

Savoring every drop – Vampire or Mosquito?

Fischer *et al.*

VIEWPOINT

Savoring every drop – Vampire or Mosquito?

Dania Patricia Fischer, Kai D Zacharowski* and Patrick Meybohm

Abstract

Blood safety with respect to infectious complications has reached very high standards. Nevertheless, reports on transfusion-associated morbidity and mortality gain momentum. Multidisciplinary patient blood management programs can minimize unnecessary exposure to allogeneic blood products by strengthening and conserving patients' own resources. This article outlines concepts designed to maintain hemoglobin concentration, to optimize hemostasis, and to minimize blood loss in ICUs. These measures prevent or at least alleviate hospital-acquired anemia, reduce the need for blood transfusions, and therefore have great potential to improve patient safety and medical outcome.

Introduction

Blood is the most precious and eclectic of fluids. Blood transports oxygen and nutrients throughout the body, heals our wounds, connects our organs, and protects us from dangerous pathogens; it is the essence through which we can remain healthy and able. Not surprisingly, the shortage of blood and especially of the associated hemoglobin - manifested clinically as anemia - negatively affects patient outcomes [1-5]. Anemia is a very common phenomenon, particularly among critically ill patients. Approximately two thirds of the patients already show a hemoglobin concentration of below 120 g/L on admission to the ICU, and after 1 week 97% are anemic [3,5,6]. This condition often results from a combination of nutritional deficiency, hemolysis, myelosuppression, renal insufficiency, and comorbidities. Unfortunately, there are no immediate remedies for anemia without side effects. Blood safety with respect to infectious complications might have reached very high standards [7], but reports on transfusion-associated morbidity and mortality continue to abound. Evidence increasingly suggests that the transfusion

of even a single allogeneic red blood cell (RBC) unit can be associated with increased morbidity and mortality because of infectious, immunological, pulmonary, and thromboembolic complications [8-11]. The creation of a suitable synthetic blood mimetic has long been sought after, yet this goal remains elusive.

This leaves practitioners facing a dilemma. On one hand, anemia should be reconciled in order for the body to function at optimal levels, yet the one immediate solution of transfusing allogeneic RBCs may harm the patient further by inducing additional adverse events. This dilemma is arguably most pressing in the ICU because patients are sickest and the close surveillance of the patients requires collection of blood for testing. However, this renders patients even more vulnerable to anemia. Shockingly, weekly blood loss due to phlebotomy and laboratory blood sampling to monitor coagulation, organ function, and acid-base status or to screen for nosocomial infections has been reported to range from 340 to 660 mL in ICU patients [12,13]. Similar observations prompted John F Burnum in 1986 to provocatively refer to physicians as 'medical vampires' [14]. Despite our good intentions, we as medical care providers often add considerably to the development of anemia by close laboratory surveillance and other blood-shedding therapeutic measures, such as dialysis.

Particularly in the setting of ICUs, a multicomponent strategy to prevent or at least ameliorate hospital-acquired anemia is needed. There are many angles from which we can tackle this issue while possibly improving outcomes and minimizing additional complications. Areas where a new standard of care could be most beneficial include the improvement of diagnostic and therapeutic procedures and the optimization of coagulation management and hemotherapy. Together, we should seek every possibility to reduce our 'appetite' for blood and move from being 'medical vampires' to 'medical mosquitoes'.

* Correspondence: kai.zacharowski@kgu.de

Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany

Blood sampling volume and frequency

The Sepsis Occurrence in Acutely Ill Patients study reported a positive correlation between severity of organ dysfunction, the number of blood draws, and the total volume drawn [5]. Admittedly, more iatrogenic blood loss was recorded in the sicker patient groups compared with relatively healthier ones, and this may confound the results as these patients were *per se* more likely to suffer from organ dysfunction due to their underlying condition. Nevertheless, it appears that iatrogenic blood loss has a negative impact on patient outcomes and therefore offers an area with great potential for improvement.

However, there is significant variation between ICUs: demographic and clinical characteristics of patients, varying surgical partners, local standards of care, and laboratory performances are but a few factors that have a large impact on the volume of blood losses. An informative first step is therefore for each hospital to keep a record on the frequency and volume of blood drawings for each patient. A simple visualization is a solid foundation to build upon in order to design methods to effectively reduce blood losses. It can also serve as a baseline to quantify and compare the effect of tailor-made solutions in instances in which a common deficiency is identified at a regional or even national level.

The frequency, volume, and process of blood drawings are rational first steps for consideration in constructing better standards of care. Firstly, scattershot laboratory testing should be avoided by carefully evaluating and streamlining the commonly used practice parameters. Establishing a task force of interdisciplinary local experts representing critical care medicine, surgery, internal medicine, infectious diseases, neurology, laboratory medicine/microbiology, and nursing staff is one approach to this. This task force should establish a consensus on parameters and frequency of laboratory testing in common situations to guide clinical practice. The consensus could be based upon evidence-based recommendations and expert opinion. An example for this is a utilization management intervention, which reduced unnecessary testing in a coronary care unit established by a multidisciplinary team at Massachusetts General Hospital (Boston, MA, USA) [15]. The team viewed the routine determination of 'extended' chemistries, such as calcium, magnesium, and phosphorus, as unsubstantiated practice in coronary care patients. The team developed guidelines and computerized order template designs discouraging the routine measurements of these electrolytes and also of arterial blood gases (ABGs) in patients not receiving ventilatory support. Tests for sodium, potassium, chloride, and complete blood counts were recommended to be ordered only once per day. Analysis of ABG measurement was recommended only after significant changes in minute ventilation, fall in oxygen saturation, or significant changes in clinical condition. Wang

and colleagues [15] specifically emphasized that blood gases did not have to be assessed with every change in ventilator setting. They were thus able to demonstrate a significant reduction in routine testing without change in clinical outcomes and saw scope for further reduction. However, the study was not powered to assess differences in clinical outcomes, historical controls were used, and the measures of severity of illness were imprecise.

Another example to improve physician test ordering might be a guideline on the evaluation of patients who develop early postoperative fever in the ICU [16]. Fever is a common phenomenon during the initial 48 hours after surgery and usually non-infectious in origin under the precondition that sterility was kept and no aspiration occurred. The guideline by O'Grady and colleagues [16] therefore recommends caution with regard to taking blood cultures in the work-up of early postoperative fever.

Recommendations on the frequency of laboratory testing should also take into account the half-life and appropriateness of clinical biomarkers: C-reactive protein (CRP), for instance, has a half-life of 19 hours and cannot be recommended as an aid to the initiation or discontinuation of any antibiotic in adults, as described by Dupuy and colleagues [17]. CRP values can never be diagnostic on their own and can be interpreted only at the bedside, in full knowledge of all other clinical and pathological results [18]. Besides, laboratory tests should be repeated only if indicated: clinicians should refrain from using prepackaged orderings and move on to hand-picked and also consider the inherent standard deviation of laboratory findings when ordering tests. In this regard, physicians should be mindful that false-positive results need control and therefore should order only the minimum requirement, thus reducing overall burden on the health-care system and reducing the risk of negative outcomes for the patient. We believe that there is great savings potential of restrictive versus standard laboratory testing.

Moreover, the process of blood drawing itself might offer scope for improvement. We encourage the introduction of in-line blood sampling devices, which can also be combined with chemistry monitors. Widness and colleagues [19], for example, could reduce cumulative phlebotomy loss by one fourth in a randomized, controlled, prospective trial on preterm infants: monitor group (n = 46) and control group (n = 47). An in-line bedside monitor was used that withdraws blood through an arterial catheter; analyzes blood gases and sodium, potassium, and hematocrit levels; and returns the sample to the patient. Through the use of in-line blood sampling devices, the same quality of care can be maintained without any increased risk of infection compared with standard arterial and venous lines while less blood is wasted [12,20]. We would argue that in-line blood sampling devices represent a realistic and effective tool in saving patients' blood.

Increased practitioner education on laboratory requirements may also reduce blood wastage. The blood diagnostics unit at the University Hospital Frankfurt, Germany, for instance, requires specimens of only 30 μL for the quantification of procalcitonin; the dead space volume needed to prime the system, however, is 300 μL . Technological innovations in the future may further reduce dead space volume requirements, and the improved preservation of blood specimens for potential subsequent use would be another beneficial area to explore. The sensible use of analytical chemistry techniques and, where applicable, the introduction of pediatric vials (having a capacity of less than 100 μL) should be considered. One study has shown that using pediatric blood collection tubes nearly halved the blood loss associated with diagnostic testing (reduction of 47%) without compromising laboratory test procedures and test quality [21]. Figure 1 illustrates adult ('vampire's appetite') versus such pediatric ('mosquito's appetite') test tubes. In this regard, using smaller tubes may have the potential to reduce the severity of phlebotomy-induced anemia in adults. However, the drawback of this is that smaller test tubes bind more human resources as they usually require manual handling, thereby increasing costs and potentially delaying analysis. Point-of-care (POC) microanalysis such as bedside tests, on the other hand, also often requires less than 500- μL specimens and has the additional advantage of short turnaround times for results, reducing staff time requirements. However, the nearness of the tests might increase the number of tests done.

Additionally, non-invasive tools for hemodynamic monitoring should be used wherever possible as indwelling catheters have been shown to increase blood testing [22]. Transcutaneous measurements of hemoglobin can also be considered, although results from non-invasive analysis

might deviate from actual values which render these methods potentially hazardous [23,24]. Further factors such as vasopressor therapy may interfere and represent another serious limitation for non-invasive hemoglobin monitoring in many ICU patients [25].

Blood-sparing techniques

Continuous dialysis is a common requirement in critical care patients and necessitates sufficient anticoagulation to prevent blood clotting; premature clotting of the dialysis circuit leads to increased blood loss for the patient. On the other hand, anticoagulation itself inherently increases bleeding risk. One therapeutic strategy that extends filter lifetime without increasing the risk of bleeding is the use of citrate-anticoagulation during dialysis. Citrate is administered in the extracorporeal circuit and chelates the calcium required in the coagulation cascade. It extends circuit survival time and filter lifetime [26,27] and furthermore is associated with a significant decrease in bleeding - relative risk (RR) 0.34, 95% CI 0.17 to 0.65 - compared with standard anticoagulation with heparin [28]. However, additional equipment and training of staff are required initially. Once citrate-anticoagulated dialysis is implemented, complication rates are low, making initial investments on monetary and human resources worthwhile in our view.

Cell salvage is another possibility which can be explored. Post-operative blood recovery techniques using cell savers are not applicable in many ICU patients but may be useful in selected cases with the critically ill. In particular, cell salvage should be one of the main cornerstones within the first hours after major surgery in coagulopathic cardiac surgery patients with increased blood loss in order to reduce the need for allogeneic RBC transfusion in ICUs.




Figure 1 Appetite for blood: medical vampire or medical mosquito? Illustration by Pia Ockelmann.

Coagulation management and hemotherapy

Hemostatic abnormalities are common among critically ill patients and often are of multifactorial origin [29]. Treatment decisions are increasingly aided by bedside coagulation monitoring, which provides reliable and fast testing of the overall hemostatic function. Goal-directed algorithms based on results from thrombelastography and rotational thromboelastometry have been shown to reliably regulate coagulopathy in studies on trauma and cardiac patients [30]. However, owing to the nature of diseases encountered in ICUs, interventions that are successful in other settings may not be relevant in the ICU setting. Furthermore, the costs of acquisition and provision of trained staff are high. But although studies on POC-guided hemotherapy algorithms in the treatment of critically ill patients are still pending and initial costs may be a deterrent, the potential to curtail blood losses is high. Coagulation management ideally should be based on a combination of aggregometric and viscoelastic diagnostic methods integrated into an algorithm already validated in other medical settings. The algorithm should emphasize the need to maintain optimal hemostatic conditions with normal pH, temperature, and calcium levels. Furthermore, it should include anti-fibrinolytic agents such as tranexamic acid and conclude with the use of recombinant activated factor VII in selected cases refractory to standard treatment [31,32]. This algorithm should also give an overview of indications for adequate hemotherapy.

RBC transfusion is a common intervention in ICU patients; approximately one third of critically ill patients receive a blood transfusion during their stay in the ICU [33]. However, RBC transfusions have been associated with worse outcomes in several populations of patients, including critically ill patients [3,5,34]. This set off a shift in transfusion policy toward a more restrictive approach encompassing lower transfusion thresholds in the critically ill [35]. Most importantly, it has been recognized that hemotherapy should be individualized in order to carefully balance the risks of allogeneic blood products with the risks of low hemoglobin levels in each single case. Presumably, not only inter-individual but also intra-individual variation exists in the tolerance toward anemia depending

on metabolic activity, volume status, physiological reserve, dynamics of the anemia, and other health issues. Generally, normovolemic anemia is better tolerated than hypovolemic anemia and chronic anemia (for instance, due to sepsis) is better tolerated than acute anemia in cases of severe uncontrolled bleeding. Therefore, transfusion decisions should be based on both symptoms as well as laboratory results such as hemoglobin concentration.

Several prospective studies on restrictive versus liberal transfusion strategies in critically ill patients exist. However, there is little evidence on safe transfusion strategies for patients with cardiovascular diseases, causing a lot of insecurity in the care of such patients [36,37]. The TRICC (Transfusion Requirements in Critical Care) trial showed in 838 ICU patients that a restrictive transfusion threshold (hemoglobin (Hb) trigger 70 g/L, target 70 to 90 g/L) compared to a liberal one (Hb trigger 100 g/L, target 100 to 120 g/L) is at least as effective [38]. However, the trial did not enroll patients with anemia, ischemic heart disease, or active bleeding. Walsh and colleagues [39] enrolled 100 ventilated ICU patients in a prospective, randomized study and found a non-significant trend toward lower mortality in the restrictive group (Hb trigger 70 g/L, target 71 to 90 g/L) compared with the liberal group (Hb trigger 90 g/L, target 91 to 110 g/L) 180 days after randomization (RR 0.68, 95% CI 0.44 to 1.05; $P = 0.073$). Thirty-two percent of the patients had ischemic heart disease. Surely, more studies will follow and hopefully provide a more definite answer as to what is safe for patients with cardiovascular diseases. Finally, we also recommend a strict 'single unit policy' with re-evaluation of the clinical situation after each unit transfused except in cases of massive bleeding.

Barriers to implementation

Synthesizing and implementing new standards of care can be very demanding. Great importance should be placed on the education of staff to change attitudes toward blood testing. It is vital to address knowledge gaps, facilitate behaviors, and reduce barriers to them. The implementation of checklists alongside training sessions of care-providing staff is a highly recommended tool to maintain adherence to new standards. Table 1

Table 1 Measures to spare patient blood

Phlebotomy losses	Coagulation management	Further approaches
<ul style="list-style-type: none"> • Quantify sampling volume and frequency 	<ul style="list-style-type: none"> • Maintain optimal hemostatic conditions (pH, Ca^{2+}, and temperature) 	<ul style="list-style-type: none"> • Non-invasive monitoring
<ul style="list-style-type: none"> • Critically assess parameters ordered 	<ul style="list-style-type: none"> • Algorithm-based hemotherapy 	<ul style="list-style-type: none"> • Citrate-anticoagulated dialysis
<ul style="list-style-type: none"> • Microchemistry techniques, possibly pediatric vials 		<ul style="list-style-type: none"> • Cell salvage
<ul style="list-style-type: none"> • Point-of-care bedside tests 		<ul style="list-style-type: none"> • Education and checklists
<ul style="list-style-type: none"> • In-line blood sampling devices 		

summarizes the different measures to limit blood loss in critically ill patients. The desired laboratory ordering behavior and the employment of blood-sparing techniques should be reinforced.

However, one should be aware of barriers to implementation. Further investigation of routine laboratory orderings may lead to the conclusion that many orderings are due primarily to real or perceived medico-legal reasons. Sincere and powerful fear of medical malpractice claims may lead to superfluous testing and controlling of more parameters than medically indicated, in order to minimize legal risks. Therefore, we would recommend engagement in introspective and collegial dialogue over professional practice and litigation risk factors to strive for better patient outcomes while reducing burdens on the health-care system. We suggest that inconsistencies be questioned, diagnostic ordering routines be revised, and anxieties concerning exposure to potential litigation and legal liability be minimized, for the benefit of our patients' clinical outcome. Furthermore, economic arguments seem to increasingly permeate many aspects of hospital routine. Although these should not guide our medical decision-making, they are vital to consider as resources are finite. Personnel and material costs need to be weighed against potential savings from better patient outcome. Limiting the use of laboratory order sets will require more attention from the whole team involved in ICU therapy, in addition to thoughtful guidance by senior physicians. It is true that individualized laboratory ordering may be more resource-intensive and also may require manual processing by the laboratory staff, especially with the use of smaller pediatric vials. In our opinion, savoring every drop of blood even has the potential to reduce costs. This is applicable both directly to blood transfusion units and to the wider economic impact of associated adverse events, from both hospital-acquired anemia and allogeneic blood transfusions [40,41]: delayed wound healing, nosocomial infections, renal insufficiency, and major adverse cardiac events, to name a few. Therefore, a medico-economic evaluation of the effects of the implementation of a bundle of measurements is worthwhile and indeed may favor the improved standards of care described here.

In conclusion, blood use in ICUs can be excessive for various reasons. Developing and adopting better standards of care can ameliorate the vicious cycle we find ourselves in now, in which superfluous testing can result in iatrogenic anemia that may necessitate subsequent RBC transfusion. The rate of allogeneic blood transfusions can be further minimized by employing restrictive transfusion policies. Combined, these multimodal patient blood management concepts have great potential to avoid transfusion-related adverse events.

Let us strive to reduce the need for allogeneic blood transfusions by preserving patients' blood and transfuse

only when absolutely necessary in order improve the quality and economy of critical care. Let us savor every drop just as a mosquito would and not drain blood from our patients like Dracula!

Abbreviations

ABG: Arterial blood gas; CRP: C-reactive protein; Hb: Hemoglobin; POC: Point-of-care; RBC: Red blood cell; RR: Relative risk.

Competing interests

The authors implemented the measures explained in the article in the framework of a Patient Blood Management Program at the University Hospital Frankfurt. This work is supported by departmental funding and by Vifor Pharma Deutschland GmbH (Muenchen, Germany), B. Braun Melsungen AG (Melsungen, Germany), CSL Behring (Marburg, Germany), and Fresenius Kabi (Bad Homburg, Germany). The authors declare that they have no further competing interests.

Acknowledgments

We thank our colleague Pia Ockelmann for drafting Figure 1 and Chris Eccles for editing of the manuscript with attention to language.

Published: 21 May 2014

References

1. Tang YD, Katz SD: **The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes.** *Heart Fail Rev* 2008, **13**:387–392.
2. Tang YD, Katz SD: **Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options.** *Circulation* 2006, **113**:2454–2461.
3. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ: **The CRIT Study: anemia and blood transfusion in the critically ill - current clinical practice in the United States.** *Crit Care Med* 2004, **32**:39–52.
4. Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, Kheiss M, Dahdaleh FS, Khavandi K, Sfeir PM, Soweid A, Hoballah JJ, Taher AT, Jamali FR: **Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study.** *Lancet* 2011, **378**:1396–1407.
5. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, Meier-Hellmann A, Nollet G, Peres-Bota D, ABC (Anemia and Blood Transfusion in Critical Care) Investigators: **Anemia and blood transfusion in critically ill patients.** *JAMA* 2002, **288**:1499–1507.
6. Thomas J, Jensen L, Nahimiak S, Gibney RT: **Anemia and blood transfusion practices in the critically ill: a prospective cohort review.** *Heart Lung* 2010, **39**:217–225.
7. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ, German Red Cross NAT Study Group: **Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.** *Transfusion* 2008, **48**:1558–1566.
8. Marik PE, Corwin HL: **Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature.** *Crit Care Med* 2008, **36**:2667–2674.
9. Shander A, Goodnough LT: **Why an alternative to blood transfusion?** *Crit Care Clin* 2009, **25**:261–277.
10. Vamvakas EC, Blajchman MA: **Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention.** *Blood* 2009, **113**:3406–3417.
11. Rohde JM, Dimcheff DE, Blumberg N, Saint S, Langa KM, Kuhn L, Hickner A, Rogers MA: **Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis.** *JAMA* 2014, **311**:1317–1326.
12. Silver MJ, Li YH, Gragg LA, Jubran F, Stoller JK: **Reduction of blood loss from diagnostic sampling in critically ill patients using a blood-conserving arterial line system.** *Chest* 1993, **104**:1711–1715.
13. Nguyen BV, Bota DP, Melot C, Vincent JL: **Time course of hemoglobin concentrations in nonbleeding intensive care unit patients.** *Crit Care Med* 2003, **31**:406–410.
14. Burnum JF: **Medical vampires.** *N Engl J Med* 1986, **314**:1250–1251.

15. Wang TJ, Mort EA, Nordberg P, Chang Y, Cadigan ME, Mylott L, Ananian LV, Thompson BT, Fessler M, Warren W, Wheeler A, Jordan M, Fifer MA: **A utilization management intervention to reduce unnecessary testing in the coronary care unit.** *Arch Intern Med* 2002, **162**:1885–1890.
16. O'Grady NP, Barie PS, Bartlett JG, Bleck T, Carroll K, Kalil AC, Linden P, Maki DG, Nierman D, Pasculle W, Masur H, American College of Critical Care Medicine; Infectious Diseases Society of America: **Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Crit Care Med and the Infectious Diseases Society of America.** *Crit Care Med* 2008, **36**:1330–1349.
17. Dupuy AM, Philippart F, Péan Y, Lasocki S, Charles PE, Chalumeau M, Claessens YE, Quenot JP, Guen CG, Ruiz S, Luyt CE, Roche N, Stahl JP, Bedos JP, Pugin J, Gauzit R, Misset B, Brun-Buisson C, Maurice Rapin Institute Biomarkers Group: **Role of biomarkers in the management of antibiotic therapy: an expert panel review: I - currently available biomarkers for clinical use in acute infections.** *Ann Intensive Care* 2013, **3**:22.
18. Pepys MB, Hirschfeld GM: **C-reactive protein: a critical update.** *J Clin Invest* 2003, **111**:1805–1812.
19. Widness JA, Madan A, Grindeanu LA, Zimmerman MB, Wong DK, Stevenson DK: **Reduction in red blood cell transfusions among preterm infants: results of a randomized trial with an in-line blood gas and chemistry monitor.** *Pediatrics* 2005, **115**:1299–1306.
20. Oto J, Nakataki E, Hata M, Tsunano Y, Okuda N, Imanaka H, Nishimura M: **Comparison of bacterial contamination of blood conservation system and stopcock system arterial sampling lines used in critically ill patients.** *Am J Infect Control* 2012, **40**:530–534.
21. Smoller BR, Kruskal MS, Horowitz GL: **Reducing adult phlebotomy blood loss with the use of pediatric-sized blood collection tubes.** *Am J Clin Pathol* 1989, **91**:701–703.
22. Low LL, Harrington GR, Stoltzfus DP: **The effect of arterial lines on blood-drawing practices and costs in intensive care units.** *Chest* 1995, **108**:216–219.
23. Frasca D, Dahyot-Fizelier C, Catherine K, Levrat Q, Debaene B, Mimoz O: **Accuracy of a continuous noninvasive hemoglobin monitor in intensive care unit patients.** *Crit Care Med* 2011, **39**:2277–2282.
24. O'Reilly M: **Understanding noninvasive and continuous hemoglobin monitoring.** *Crit Care Med* 2013, **41**:e52.
25. Coquin J, Dewitte A, Manach YL, Caujolle M, Joannes-Boyau O, Fleureau C, Janvier G, Ouattara A: **Precision of noninvasive hemoglobin-level measurement by pulse co-oximetry in patients admitted to intensive care units for severe gastrointestinal bleeds.** *Crit Care Med* 2012, **40**:2576–2582.
26. Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T: **Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system.** *J Crit Care* 2005, **20**:155–161.
27. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: **Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study.** *Intensive Care Med* 2004, **30**:260–265.
28. Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, Tam KW: **Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials.** *Am J Kidney Dis* 2012, **59**:810–818.
29. Levi M, Opal SM: **Coagulation abnormalities in critically ill patients.** *Crit Care* 2006, **10**:222.
30. Weber CF, Grolinger K, Meininger D, Herrmann E, Bingold T, Moritz A, Cohn LH, Zacharowski K: **Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients.** *Anesthesiology* 2012, **117**:531–547.
31. Tanaka KA, Bader SO, Grolinger K: **Novel approaches in management of perioperative coagulopathy.** *Curr Opin Anaesthesiol* 2014, **27**:72–80.
32. Dietrich W, Faraoni D, von Heymann C, Bolliger D, Ranucci M, Sander M, Rosseel P: **ESA guidelines on the management of severe perioperative bleeding: comments on behalf of the Subcommittee on Transfusion and Haemostasis of the European Association of Cardiothoracic Anaesthesiologists.** *Eur J Anaesthesiol* 2014, **31**:239–241.
33. Lelubre C, Vincent JL: **Red blood cell transfusion in the critically ill patient.** *Ann Intensive Care* 2011, **1**:43.
34. Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani DC: **Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion.** *Crit Care Med* 2005, **33**:1191–1198.
35. Gombotz H, Zacharowski K, Spahn DR: *Patient Blood Management: Individuelles Behandlungskonzept zur Reduktion und Vermeidung von Anämie*, [Patient Blood Management: Individualized concept to reduce and avoid anemia]. 1st edition. Stuttgart: Thieme Verlag Stuttgart; 2013.
36. Walsh TS, McClelland DB, Lee RJ, Garrioch M, Maciver CR, McArdle F, Crofts SL, Mellor I, Group AS: **Prevalence of ischaemic heart disease at admission to intensive care and its influence on red cell transfusion thresholds: multicentre Scottish Study.** *Br J Anaesth* 2005, **94**:445–452.
37. Carson JL, Carless PA, Hebert PC: **Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion.** *Cochrane Database Syst Rev* 2012, **4**, CD002042.
38. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E: **A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.** *N Engl J Med* 1999, **340**:409–417.
39. Walsh TS, Boyd JA, Watson D, Hope D, Lewis S, Krishan A, Forbes JF, Ramsay P, Pearse R, Wallis C, Cairns C, Cole S, Wyncoll D, RELIEVE Investigators: **Restrictive versus liberal transfusion strategies for older mechanically ventilated critically ill patients: a randomized pilot trial.** *Crit Care Med* 2013, **41**:2354–2363.
40. Hofmann A, Ozawa S, Farrugia A, Farmer SL, Shander A: **Economic considerations on transfusion medicine and patient blood management.** *Best Pract Res Clin Anaesthesiol* 2013, **27**:59–68.
41. Loor G, Rajeswaran J, Li L, Sabik JF 3rd, Blackstone EH, McCrae KR, Koch CG: **The least of 3 evils: exposure to red blood cell transfusion, anemia, or both?** *J Thorac Cardiovasc Surg* 2013, **146**:1480–1487. e1486.

10.1186/cc13884

Cite this article as: Fischer et al.: **Savoring every drop – Vampire or Mosquito?** *Critical Care* 2014, **18**:306